Elizabeth Yurth

Coverage status — October 2026: Yurth is a clinician-educator, not an administration official. She is tracked here as the clinician face of the peptide-access campaign inside the Kennedy FDA’s highest-profile drug fight of 2026 — a role that culminated in her July 2026 testimony before the FDA’s Pharmacy Compounding Advisory Committee (PCAC), where she argued for physician-supervised peptide access (per her own Hone Health article). The committee voted to recommend 6 of the 7 nominated peptides for the 503A Bulks List.

Her credentials are clinical: double board certification in physical medicine & rehabilitation and in anti-aging/regenerative medicine, a Stanford-affiliated sports/spine fellowship, and faculty roles with A4M and the International Peptide Society, where she is an SSRP mastermind fellow. On the clinician podcast circuit she teaches the compounds at the center of the current fight — BPC-157, TB-4, growth-hormone secretagogues, GHK-Cu, and GLP-1s — as she presents them to other physicians.

The conflict, stated plainly: Yurth is an educator with a clinic. The Boulder Longevity Institute, which she co-founded, prescribes peptides in its practice, and BLI Academy sells education to clinicians. No research-chemical shop or discount codes were found attached to her name — but her testimony advocacy and her clinic’s commercial interest point in the same direction, and this site reports both.

Why tracked here: when the FDA decides which peptides Americans can legally get through compounding pharmacies, Yurth is the credentialed clinician the access campaign puts in front of the committee — her testimony is part of the primary record of that fight.

Sources (Oct 2026): Hone Health (Yurth’s own account of her PCAC testimony, July 2026); FDA Pharmacy Compounding Advisory Committee proceedings, July 2026; Boulder Longevity Institute, A4M, and International Peptide Society faculty listings.